在患有晚期非小细胞和小细胞肺癌的患者中,超过疾病进展的持续免疫疗法
Jing Cheng1, Wenwen Kang1, Yueying Chen1
1Department of Respiratory and Critical Care Medicine, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Cancer immunology, immunotherapy : CII
|February 25, 2025
概括
疾病进展后继续免疫疗法对特定的肺癌患者有好处. 这种方法改善了驱动基因阴性非小细胞肺癌和小细胞肺癌患者的生存率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肺癌研究研究 肺癌研究
背景情况:
- 在晚期非小细胞肺癌 (NSCLC) 和小细胞肺癌 (SCLC) 中,在疾病进展后继续免疫治疗的疗效尚未得到充分证实.
- 确定从这种策略中获益最多的患者子组对于优化治疗结果至关重要.
研究的目的:
- 评估持续免疫疗法在进展后作为高级NSCLC和SCLC的二线治疗的有效性.
- 确定最有可能从这种治疗方法中受益的特定患者群体.
主要方法:
- 在初始免疫检查点抑制剂 (ICI) 治疗后进展的NSCLC和SCLC150名患者的回顾性分析.
- 在接受免疫疗法超出进展 (IBP) 和接受非免疫疗法超出进展 (NIBP) 的患者之间比较生存结果和安全性.
主要成果:
- 与NIBP相比,患有驱动基因阴性NSCLC和SCLC的患者表现出明显改善的IBP无进展存活率 (PFS) 和整体存活率 (OS).
- 在驱动基因阴性NSCLC中,最初的部分反应或稳定的疾病与持续免疫治疗的更好的结果相关.
- 具体生存数据:驱动基因阴性NSCLC (mPFS:4.7与1.3个月;mOS:11.03与2.63个月) 和SCLC (mPFS:3.9与2.1个月;mOS:9.28与2.27个月).
结论:
- 在进展后继续免疫治疗可能是对驱动基因阴性NSCLC和SCLC患者有益的二线治疗策略.
- 这种方法为精选的肺癌患者提供了潜在的生存优势,这些患者在初始免疫治疗后进展.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.8K
相关概念视频
Tumor Immunotherapy
462
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
462
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Vaccines
325
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
325
